Current Concepts in Joint Replacement Winter Meeting
Current Concepts in Joint Replacement Winter Meeting
December 18, 2019
1 min read
Save

Cefazolin may be safe for patients with penicillin allergy

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

David G. Lewallen

ORLANDO — Treatment with cefazolin may be safe in patients who report a penicillin allergy, may reduce the rate of infection and provide cost-savings in patients undergoing total joint replacement, according to a presenter at the Current Concepts in Joint Replacement Winter Meeting.

Although cefazolin is the gold standard for prophylaxis in patients undergoing TJR, David G. Lewallen, MD, noted 10% to 15% of patients self-report a penicillin allergy, which may lead to a cross reaction when cephalosporins are used. However, despite the common report of penicillin allergies, Lewallen said it is rarely true, with 1% to 10% of patients being confirmed with a penicillin allergy.

“The report of this results in changes in antibiotics and a 50% increase in surgical site infection rates in some reported series and the risk of getting MRSA goes up when you use alternatives to cephalosporins and a 26% increase of [Clostridioides difficile],” Lewallen said in his presentation here.

A study published by Lewallen and colleagues showed among approximately 3,400 patients who underwent allergy screening prior to surgery, 97% were cleared for cephalosporin use and 85% of patients received cephalosporin at the time of surgery. Lewallen added patients who received a non-cephazolin prophylaxis had a 32% increased risk for periprosthetic infection.

“We test all patients, or we recommend that, with a question of allergy, we try to do that, and we use cephazolin whenever we can, when it is deemed safe,” Lewallen said. – by Casey Tingle

 

References:

Lewallen DG. Paper 116. Presented at: Current Concepts in Joint Replacement Winter Meeting; Dec. 11-14, 2019; Orlando.

 

Wyles CC, et al. Bone Joint J. 2019;doi;10.1302/0301-620X.101B6.BJJ-2018-1407.R1.

 

Disclosure: Lewallen reports he has stock in Acuitive Technologies and Ketai Medical Devices; is a paid consultant for Acuitive Technologies and Zimmer Biomet; and receives royalties from MAKO/Stryker and Zimmer Biomet.